Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 22;8:994. doi: 10.3389/fimmu.2017.00994

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 Hall, Robinson, Plain, Verma, Tran, Nomura, Carter, Boyd and Hodgkinson.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Immunostaining of peripheral lymphocytes: comparison of cells from DA rats tolerant to a Piebald Virol Glaxo rat strain (PVG) allograft and naïve DA. (A) FACS profiles of lymphocytes from naïve DA rats (upper panel) and DA rats tolerant to PVG heart graft (lower panel). y-axis represents CD4 and x-axis CD8 (left panel), CD25 (middle panel), and forkhead box P3 (FOXP3) (right panel). (B) Percentage of cells expressing a given cell surface molecule in naïve (○) and tolerant (●) animals, results from 4–16 different sets of animals. There was no significant difference in the proportion of CD4⁺ or CD8⁺ T cells showing anti-CD3 therapy did not deplete T cells. There was no increase in B cells with tolerance. The proportion of CD4⁺CD25⁺ T cells or CD25⁺FOXP3⁺ T cells was not increased in tolerant animals.